Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
NCT ID: NCT06882096
Last Updated: 2025-05-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
32 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-04-28
Study Completion Date
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
NCT05517122
Healthy
COMPLETED
NA
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT06919328
Healthy Aging
RECRUITING
NA
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
NCT06005350
NAD
ACTIVE_NOT_RECRUITING
NA
Measurement of NAD+ Synthesis in Human Skeletal Muscle
NCT04905446
Skeletal Muscle
COMPLETED
NA
The Effect of NAD Supplementation on Brain Vascular Health in Aging
NCT05483465
Aging
RECRUITING
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background and Significance
1.1 Role of NAD+ in Physiology Nicotinamide adenine dinucleotide (NAD+) is a key coenzyme in all living organisms, existing in oxidized (NAD+) and reduced (NADH) forms. Beyond its vital role in redox reactions and ATP generation, NAD+ also serves as a co-substrate for several signaling enzymes such as sirtuins, PARPs, and CD38. Systemic NAD+ insufficiency can cause diseases like pellagra; reduced NAD+ availability has been implicated in aging and age-related disorders.
1.2 Oral NAD+ Precursors Administration of NAD+ precursors (e.g., NMN, NR, NAM) can boost NAD+ levels. Although human research has shown that oral NMN raises blood NAD+ concentrations, many aspects of its absorption, metabolism, and overall bioavailability are still poorly understood. Rodent studies suggest oral NMN undergoes extensive first-pass metabolism in the gut, with partial conversion to NAM prior to entering systemic circulation.
1.3 Aging and NAD+ In rodent models, NAD+ levels frequently decline as the animals get older. Some evidence indicates that NAD+ turnover may be elevated in aging rodents, suggesting a higher rate of NAD+ consumption. However, equivalent tracer studies have not yet been conducted in humans.
1.4 Need for Human Tracer Studies These compounds are being investigated for the prevention and treatment of age-related diseases. There is a need to clarify how they are absorbed and how exactly they elevate NAD+ in different tissues. Using stable isotope-labeled NMN and NAM will help map the flux from oral precursors into blood, muscle, urine, and stool, and will also reveal how aging influences NAD+ turnover.
2\. Aims and Objectives
Aim 1: Use stable isotope tracers and mass spectrometry in healthy young adults to track how orally administered NMN or NAM are metabolized, how they enter NAD+ pools, and how much is excreted or converted to other metabolites.
Aim 2: Compare these same fluxes in older adults (≥65 years). Investigators specifically want to see whether age alters the metabolic route from precursor to NAD+ and whether older adults exhibit higher consumption (turnover) of NAD+.
3\. Study Design
3.1 Overview Single-center trial at Brigham and Women's Hospital.
Groups: Two main groups of participants:
Group A (NMN group): 16 participants (8 young adults aged 18-40; 8 older adults aged ≥65).
Group B (NAM group): 16 participants (8 young; 8 older). Each participant takes either NMN or NAM orally for 14 days. The study uses stable isotopes (non-radioactive) to label NMN or NAM in order to track how these molecules appear in NAD+ and its downstream metabolites.
3.2 Treatment Duration Participants receive daily doses of their assigned treatment (NMN or NAM) for 14 days. Detailed sampling done on Days 1 and 14.
3.3 Dosage NMN: 1000 mg once daily (four 250 mg capsules). NAM: 370 mg once daily. On Days 1 and 14, the entire oral dose is fully labeled with stable isotopes; on the intermediate days (2-13), the product is unlabeled.
3.4 Key Assessments Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr) on Days 1 and 14.
Muscle biopsies of the vastus lateralis (Days 1 and 14, typically \~6-8 hours after dose) to determine how much labeled precursor appears in muscle NAD+ pools.
Timed Collection of urine and stool on Days 1-2 and 14-15 to see how the precursor or NAD+ metabolites are excreted and to characterize gut microbiome (which can influence NAD+ precursor metabolism and may be affected by NMN or NAM).
4\. Endpoints
Primary Endpoints (for NMN group) Fraction of peripheral blood NAD+ containing the stable isotope labelled tracer
Primary Endpoints (for NAM group) Fraction of peripheral blood NAD+ containing the stable isotope labelled tracer
5\. Study Procedures Screening Phase (up to 4 weeks before Day 1) Medical history, demographics, laboratory tests (CBC, chemistry, A1C), physical exam, and EKG if indicated.
Confirm eligibility. Intervention Phase (Days 1-14)
Day 1:
Collect baseline blood samples and muscle biopsy. Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr).
Administer stable-isotope-labeled product (NMN or NAM) at time 0. Repeat blood draws at specified intervals. Collect urine and stool.
Day 2:
Additional blood draws. Begin taking unlabeled study product daily at home.
Days 3, 5, 8:
Short visits for blood sampling, vital signs, adherence check.
Day 14:
Collect baseline blood samples and muscle biopsy. Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr).
Administer stable-isotope-labeled product (NMN or NAM) at time 0. Collect urine and stool.
Day 15:
Unlabeled Treatment (NAM or NMN) administration. Follow-up blood draws.
Follow-up Phase:
Days 16, 43:
Final safety labs, check for adverse events, measure any labeled/unlabeled NAD+ or metabolites that might linger.
6\. Risks and Safety
Drug Safety:
Previous Phase 1 trials show 1000 mg NMN up to twice daily is safe and well-tolerated, with no serious drug-related adverse events.
NAM is generally recognized as safe at these doses. High-dose niacin can cause flushing, GI disturbance, or liver enzyme elevations, but those have not been seen with NMN or NAM.
Muscle Biopsy:
Potential for temporary discomfort, bruising, or rare infection at the biopsy site. The team will use local anesthetic and standard sterile technique.
Blood Draws:
Common risks include transient pain or bruising, and rarely infection.
Urine and Stool Collection:
Main risk is inconvenience and mild discomfort; no significant medical risk from the collection itself.
Adverse Events Reporting:
The protocol specifies regular monitoring and reporting. A Safety Review Committee (SRC) meets every six months.
7\. Statistical Analysis
Primary Analyses:
Quantify the fraction of labeled NAD+ vs. unlabeled in blood, PBMCs, muscle, urine, and stool.
Compare young vs. older adults to see whether aging shifts the route or magnitude of NAD+ precursor metabolism.
Models:
Mixed-model repeated measures (MMRM) or ANCOVA with factors for age, sex, and baseline values.
Sample Size:
16 subjects per arm (8 young + 8 older in NMN group; 8 young + 8 older in NAM group) is based on pilot data and the specialized nature of stable-isotope tracing.
8\. Study Conduct and Logistics
Randomization:
1:1 ratio to NMN vs. NAM, block-randomized, stratified by age group.
Blinding:
The protocol is an open-label comparison of two labeled precursors.
Data Management:
Electronic CRFs, redcap database, verification by investigators.
Monitoring:
Internal team plus sponsor oversight.
Ethical Considerations:
IRB approval, informed consent detailing objectives, procedures, and risks. Emphasis on ensuring participant safety.
9\. Importance and Potential Impact
The protocol addresses critical gaps in knowledge like how orally ingested NAD+ precursors (NMN, NAM) become NAD+ in human tissues.
Results will inform whether older adults have distinctly higher NAD+ turnover and might respond differently to NAD+ augmentation.
Findings could shape clinical dosing recommendations for NMN/NAM in therapeutic or preventive settings related to aging and metabolic health.
1.1 Role of NAD+ in Physiology Nicotinamide adenine dinucleotide (NAD+) is a key coenzyme in all living organisms, existing in oxidized (NAD+) and reduced (NADH) forms. Beyond its vital role in redox reactions and ATP generation, NAD+ also serves as a co-substrate for several signaling enzymes such as sirtuins, PARPs, and CD38. Systemic NAD+ insufficiency can cause diseases like pellagra; reduced NAD+ availability has been implicated in aging and age-related disorders.
1.2 Oral NAD+ Precursors Administration of NAD+ precursors (e.g., NMN, NR, NAM) can boost NAD+ levels. Although human research has shown that oral NMN raises blood NAD+ concentrations, many aspects of its absorption, metabolism, and overall bioavailability are still poorly understood. Rodent studies suggest oral NMN undergoes extensive first-pass metabolism in the gut, with partial conversion to NAM prior to entering systemic circulation.
1.3 Aging and NAD+ In rodent models, NAD+ levels frequently decline as the animals get older. Some evidence indicates that NAD+ turnover may be elevated in aging rodents, suggesting a higher rate of NAD+ consumption. However, equivalent tracer studies have not yet been conducted in humans.
1.4 Need for Human Tracer Studies These compounds are being investigated for the prevention and treatment of age-related diseases. There is a need to clarify how they are absorbed and how exactly they elevate NAD+ in different tissues. Using stable isotope-labeled NMN and NAM will help map the flux from oral precursors into blood, muscle, urine, and stool, and will also reveal how aging influences NAD+ turnover.
2\. Aims and Objectives
Aim 1: Use stable isotope tracers and mass spectrometry in healthy young adults to track how orally administered NMN or NAM are metabolized, how they enter NAD+ pools, and how much is excreted or converted to other metabolites.
Aim 2: Compare these same fluxes in older adults (≥65 years). Investigators specifically want to see whether age alters the metabolic route from precursor to NAD+ and whether older adults exhibit higher consumption (turnover) of NAD+.
3\. Study Design
3.1 Overview Single-center trial at Brigham and Women's Hospital.
Groups: Two main groups of participants:
Group A (NMN group): 16 participants (8 young adults aged 18-40; 8 older adults aged ≥65).
Group B (NAM group): 16 participants (8 young; 8 older). Each participant takes either NMN or NAM orally for 14 days. The study uses stable isotopes (non-radioactive) to label NMN or NAM in order to track how these molecules appear in NAD+ and its downstream metabolites.
3.2 Treatment Duration Participants receive daily doses of their assigned treatment (NMN or NAM) for 14 days. Detailed sampling done on Days 1 and 14.
3.3 Dosage NMN: 1000 mg once daily (four 250 mg capsules). NAM: 370 mg once daily. On Days 1 and 14, the entire oral dose is fully labeled with stable isotopes; on the intermediate days (2-13), the product is unlabeled.
3.4 Key Assessments Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr) on Days 1 and 14.
Muscle biopsies of the vastus lateralis (Days 1 and 14, typically \~6-8 hours after dose) to determine how much labeled precursor appears in muscle NAD+ pools.
Timed Collection of urine and stool on Days 1-2 and 14-15 to see how the precursor or NAD+ metabolites are excreted and to characterize gut microbiome (which can influence NAD+ precursor metabolism and may be affected by NMN or NAM).
4\. Endpoints
Primary Endpoints (for NMN group) Fraction of peripheral blood NAD+ containing the stable isotope labelled tracer
Primary Endpoints (for NAM group) Fraction of peripheral blood NAD+ containing the stable isotope labelled tracer
5\. Study Procedures Screening Phase (up to 4 weeks before Day 1) Medical history, demographics, laboratory tests (CBC, chemistry, A1C), physical exam, and EKG if indicated.
Confirm eligibility. Intervention Phase (Days 1-14)
Day 1:
Collect baseline blood samples and muscle biopsy. Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr).
Administer stable-isotope-labeled product (NMN or NAM) at time 0. Repeat blood draws at specified intervals. Collect urine and stool.
Day 2:
Additional blood draws. Begin taking unlabeled study product daily at home.
Days 3, 5, 8:
Short visits for blood sampling, vital signs, adherence check.
Day 14:
Collect baseline blood samples and muscle biopsy. Blood draws at multiple time points (e.g., pre-dose, 30 min, 1 hr, 2 hr, 4 hr, 8 hr).
Administer stable-isotope-labeled product (NMN or NAM) at time 0. Collect urine and stool.
Day 15:
Unlabeled Treatment (NAM or NMN) administration. Follow-up blood draws.
Follow-up Phase:
Days 16, 43:
Final safety labs, check for adverse events, measure any labeled/unlabeled NAD+ or metabolites that might linger.
6\. Risks and Safety
Drug Safety:
Previous Phase 1 trials show 1000 mg NMN up to twice daily is safe and well-tolerated, with no serious drug-related adverse events.
NAM is generally recognized as safe at these doses. High-dose niacin can cause flushing, GI disturbance, or liver enzyme elevations, but those have not been seen with NMN or NAM.
Muscle Biopsy:
Potential for temporary discomfort, bruising, or rare infection at the biopsy site. The team will use local anesthetic and standard sterile technique.
Blood Draws:
Common risks include transient pain or bruising, and rarely infection.
Urine and Stool Collection:
Main risk is inconvenience and mild discomfort; no significant medical risk from the collection itself.
Adverse Events Reporting:
The protocol specifies regular monitoring and reporting. A Safety Review Committee (SRC) meets every six months.
7\. Statistical Analysis
Primary Analyses:
Quantify the fraction of labeled NAD+ vs. unlabeled in blood, PBMCs, muscle, urine, and stool.
Compare young vs. older adults to see whether aging shifts the route or magnitude of NAD+ precursor metabolism.
Models:
Mixed-model repeated measures (MMRM) or ANCOVA with factors for age, sex, and baseline values.
Sample Size:
16 subjects per arm (8 young + 8 older in NMN group; 8 young + 8 older in NAM group) is based on pilot data and the specialized nature of stable-isotope tracing.
8\. Study Conduct and Logistics
Randomization:
1:1 ratio to NMN vs. NAM, block-randomized, stratified by age group.
Blinding:
The protocol is an open-label comparison of two labeled precursors.
Data Management:
Electronic CRFs, redcap database, verification by investigators.
Monitoring:
Internal team plus sponsor oversight.
Ethical Considerations:
IRB approval, informed consent detailing objectives, procedures, and risks. Emphasis on ensuring participant safety.
9\. Importance and Potential Impact
The protocol addresses critical gaps in knowledge like how orally ingested NAD+ precursors (NMN, NAM) become NAD+ in human tissues.
Results will inform whether older adults have distinctly higher NAD+ turnover and might respond differently to NAD+ augmentation.
Findings could shape clinical dosing recommendations for NMN/NAM in therapeutic or preventive settings related to aging and metabolic health.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Healthy Adults
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NMN- Nicotinamide Mononucleotide
This arm will include 16 participants (8 young and 8 older adults) who will receive NMN once daily for 14 consecutive days.
Group Type
ACTIVE_COMPARATOR
Nicotinamide Mononucleotide (NMN)
Intervention Type
DRUG
Nicotinamide Mononucleotide (NMN)
NAM- Nicotinamide
This arm will include 16 participants (8 young and 8 older adults) who will receive NAM once daily for 14 consecutive days.
Group Type
ACTIVE_COMPARATOR
Nicotinamide (NAM)
Intervention Type
DRUG
Nicotinamide (NAM)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide Mononucleotide (NMN)
Nicotinamide Mononucleotide (NMN)
Intervention Type
DRUG
Nicotinamide (NAM)
Nicotinamide (NAM)
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A participant may be enrolled if he/she is:
1. A healthy, community-living, man or a woman between 18 and 40 years, inclusive or 65 years or older
2. Has a body mass index (BMI) between 19 and 35 kg/m2, inclusive
3. Is free from clinically significant medical problems as determined by the Investigator
4. Is capable of providing written informed consent.
5. Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act.
1. A healthy, community-living, man or a woman between 18 and 40 years, inclusive or 65 years or older
2. Has a body mass index (BMI) between 19 and 35 kg/m2, inclusive
3. Is free from clinically significant medical problems as determined by the Investigator
4. Is capable of providing written informed consent.
5. Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act.
Exclusion Criteria
A subject may not be enrolled if s/he:
1. Has AST or ALT \> 2 times the upper limit of normal
2. Hematocrit \< 36% or \> 51% for men, or \< 35% to \> 48% for women
3. Diagnosis of diabetes, using diabetes medications or an A1C \> 6.4%
4. Serum creatinine \> 2.0 mg/dL or eGFR \<60 mL/min
5. Prohibited medications and substances: use of anabolic steroids, rhGH, DHEA, androstenedione, or any performance enhancing drug; Current use of opiates, amphetamine, cannabinoids and cocaine
6. Use of any dietary supplement. Subjects who are using a supplement containing NAM (or niacin or NMN or NR) may be included if they agree to stop supplement at least 2 weeks before randomization.
7. For women only: Pregnant or planning to get pregnant over the next 6 months, or lactating
8. Participation in an investigational trial within the past 3 months
9. Other medical conditions which, in the opinion of the investigator, would jeopardize safety or impact the validity of the study results
For women only:
Female of childbearing age: Use of oral contraceptives is allowed provided the contraceptive regimen was initiated at least 3 months before randomization and the participant agrees not to change the regimen during the course of the study.
Excluded Medications and Treatments
1. The ingestion of the following is prohibited during 14 days prior to Day 0 and for the duration of the intervention period:
* Products that contain niacin, nicotinic acid, nicotinamide in any form, other than natural foods
* Herbal supplements
2. Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 3 month is prohibited.
1. Has AST or ALT \> 2 times the upper limit of normal
2. Hematocrit \< 36% or \> 51% for men, or \< 35% to \> 48% for women
3. Diagnosis of diabetes, using diabetes medications or an A1C \> 6.4%
4. Serum creatinine \> 2.0 mg/dL or eGFR \<60 mL/min
5. Prohibited medications and substances: use of anabolic steroids, rhGH, DHEA, androstenedione, or any performance enhancing drug; Current use of opiates, amphetamine, cannabinoids and cocaine
6. Use of any dietary supplement. Subjects who are using a supplement containing NAM (or niacin or NMN or NR) may be included if they agree to stop supplement at least 2 weeks before randomization.
7. For women only: Pregnant or planning to get pregnant over the next 6 months, or lactating
8. Participation in an investigational trial within the past 3 months
9. Other medical conditions which, in the opinion of the investigator, would jeopardize safety or impact the validity of the study results
For women only:
Female of childbearing age: Use of oral contraceptives is allowed provided the contraceptive regimen was initiated at least 3 months before randomization and the participant agrees not to change the regimen during the course of the study.
Excluded Medications and Treatments
1. The ingestion of the following is prohibited during 14 days prior to Day 0 and for the duration of the intervention period:
* Products that contain niacin, nicotinic acid, nicotinamide in any form, other than natural foods
* Herbal supplements
2. Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 3 month is prohibited.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metro International Biotech, LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shalender Bhasin
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shalender Bhasin, MB, BS
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hosptial
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Sauve AA, Wang Q, Zhang N, Kang S, Rathmann A, Yang Y. Triple-Isotope Tracing for Pathway Discernment of NMN-Induced NAD+ Biosynthesis in Whole Mice. Int J Mol Sci. 2023 Jul 5;24(13):11114. doi: 10.3390/ijms241311114.
Reference Type
BACKGROUND
Amjad S, Nisar S, Bhat AA, Shah AR, Frenneaux MP, Fakhro K, Haris M, Reddy R, Patay Z, Baur J, Bagga P. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol Metab. 2021 Jul;49:101195. doi: 10.1016/j.molmet.2021.101195. Epub 2021 Feb 17.
Reference Type
BACKGROUND
Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):90-96. doi: 10.1093/gerona/glac049.
Reference Type
BACKGROUND
Pencina KM, Valderrabano R, Wipper B, Orkaby AR, Reid KF, Storer T, Lin AP, Merugumala S, Wilson L, Latham N, Ghattas-Puylara C, Ozimek NE, Cheng M, Bhargava A, Memish-Beleva Y, Lawney B, Lavu S, Swain PM, Apte RS, Sinclair DA, Livingston D, Bhasin S. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1968-1980. doi: 10.1210/clinem/dgad027.
Reference Type
BACKGROUND
Dutta T, Kapoor N, Mathew M, Chakraborty SS, Ward NP, Prieto-Farigua N, Falzone A, DeLany JP, Smith SR, Coen PM, DeNicola GM, Gardell SJ. Source of nicotinamide governs its metabolic fate in cultured cells, mice, and humans. Cell Rep. 2023 Mar 28;42(3):112218. doi: 10.1016/j.celrep.2023.112218. Epub 2023 Mar 9.
Reference Type
BACKGROUND
Kim LJ, Chalmers TJ, Madawala R, Smith GC, Li C, Das A, Poon EWK, Wang J, Tucker SP, Sinclair DA, Quek LE, Wu LE. Host-microbiome interactions in nicotinamide mononucleotide (NMN) deamidation. FEBS Lett. 2023 Sep;597(17):2196-2220. doi: 10.1002/1873-3468.14698. Epub 2023 Aug 9.
Reference Type
BACKGROUND
Xiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. Antioxid Redox Signal. 2018 Jan 20;28(3):251-272. doi: 10.1089/ars.2017.7216. Epub 2017 Jul 28.
Reference Type
BACKGROUND
Chellappa K, McReynolds MR, Lu W, Zeng X, Makarov M, Hayat F, Mukherjee S, Bhat YR, Lingala SR, Shima RT, Descamps HC, Cox T, Ji L, Jankowski C, Chu Q, Davidson SM, Thaiss CA, Migaud ME, Rabinowitz JD, Baur JA. NAD precursors cycle between host tissues and the gut microbiome. Cell Metab. 2022 Dec 6;34(12):1947-1959.e5. doi: 10.1016/j.cmet.2022.11.004.
Reference Type
BACKGROUND
Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocr Rev. 2023 Nov 9;44(6):1047-1073. doi: 10.1210/endrev/bnad019.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MBT-1918/1932-MET
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue
NCT06627868
NOT_YET_RECRUITING
NA
Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort
NCT07336836
COMPLETED
EARLY_PHASE1
NAD Supplementation Study
NCT03310034
TERMINATED
NA
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults
NCT04862338
COMPLETED
NA
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
NCT02921659
COMPLETED
PHASE1/PHASE2
IV Administration of ChromaDex's Niagen® as Compared to NAD+
NCT06382688
ACTIVE_NOT_RECRUITING
NA
The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations.
NCT06219161
COMPLETED
NA
Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
NCT03707652
COMPLETED
NA
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
NCT06505967
RECRUITING
NA
Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity
NCT06425042
RECRUITING
NA
NAD+ Oral Supplement Pilot Intervention in Adult Females
NCT06579209
RECRUITING
NA
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
NCT06907329
RECRUITING
NA
Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia
NCT04999488
WITHDRAWN
EARLY_PHASE1
NR Supplementation and Exercise
NCT04907110
COMPLETED
NA
Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels
NCT07132801
NOT_YET_RECRUITING
NA
Effects of NAD3 Supplementation on Biomarkers of Aging
NCT04276948
COMPLETED
NA
A Study Investigating the Effects of Niagen™ in Healthy Adults.
NCT02712593
COMPLETED
PHASE2
To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults
NCT04823260
COMPLETED
NA
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype
NCT02950441
UNKNOWN
PHASE2
Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans
NCT04851288
ACTIVE_NOT_RECRUITING
PHASE2
Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults
NCT07284225
NOT_YET_RECRUITING
NA
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
NCT02721537
COMPLETED
NA
Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress
NCT02132091
COMPLETED
NA
Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function
NCT03151239
COMPLETED
NA